

# MILES UK Registry

A study to evaluate the safety and efficacy of the BioMime sirolimus eluting coronary stent system in all comers real world population with coronary artery stenosis in United Kingdom

## Study Design

- Prospective, Multicenter, Single Arm, Observational Clinical Registry
- 14 centres in United Kingdom

<b>Integrated Research Application System No.</b>	135437
<b>Study Objectives</b>	<ul style="list-style-type: none"><li>• Primary objectives: The primary objective of this study is to evaluate the Safety and Efficacy of BioMime Sirolimus Eluting coronary Stent System in real world all comers Population</li><li>• Secondary objectives:<ol style="list-style-type: none"><li>1) To evaluate frequency of Target Vessel Failure</li><li>2) To evaluate the efficacy of the device by evaluating the frequency of Clinically Driven Target Vessel Revascularization</li><li>3) To evaluate clinical safety of device in terms of Deaths and Myocardial Infarction up to 2 years</li><li>4) To evaluate Stent Thrombosis up to 2 years</li></ol></li></ul>
<b>Primary Endpoints</b>	<ul style="list-style-type: none"><li>• Efficacy: Rate of Target Vessel Failure at 9 months</li><li>• Safety: Rate of Stent Thrombosis (ARC “definite” or “probable”) in presence of dual antiplatelet therapy</li></ul>
<b>Secondary Endpoints</b>	<ul style="list-style-type: none"><li>• Cumulative Target Vessel Failure at 1, 9, 12 and 24 months</li><li>• Target Lesion Revascularization at 1, 9, 12 and 24 months</li><li>• Major Adverse Cardiac Events at 1, 9, 12 and 24 months</li><li>• Frequency of Stent Thrombosis<ol style="list-style-type: none"><li>a) Acute (0-24 hours after stent implant)</li><li>b) Sub acute (24 hours to 1 month after stent implant)</li><li>c) Late (1 month to 1 year after stent implant)</li></ol></li></ul>

	d) Very Late (Beyond 1 year after stent Implant) e) By ARC definitions: Definite, Probable and Possible, at all follow up visits
<b>Clinical Sites</b>	14 centres in United Kingdom
<b>Sample Size</b>	750 subjects
<b>Follow-Up</b>	Clinical/Telephonic follow-up at 30 days, 9 months, 1 year, and 2 years
<b>Study Duration</b>	Study start date October 2013 Estimated study completion October 2020

## ❖ References

Integrated Research Application System (IRAS) No.: 135437